News & Events

Cambridge, MA, February 5, 2007- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference and at the BIO CEO & Investor Conference.

Ian Smith, Executive Vice President and Chief Financial Officer, will present at the Merrill Lynch Conference on Wednesday, February 7, 2007 at 3:20 p.m. EST.

John Alam, M.D., Executive Vice President, Medicines Development and Chief Medical Officer, will present at BIO CEO & Investor Conference on Monday, February 12, 2007 at 2:45 p.m. EST.

The presentations will be webcast live and may be accessed from the 'Events Calendar' on the home page of Vertex's website at www.vrtx.com. A replay of the webcasts will also be available on the Company's website for two weeks following the presentations. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Vertex Contact:
Lora Pike, Manager, Investor Relations, (617) 444-6755